Posted in | News | Nanolithography

D2S Acquires Developer of GPGPU-Based Computational Lithography Acceleration Technology

D2S®, a supplier of computational design platforms based on eBeam and general purpose graphic processing unit (GPGPU) technologies, today announced that it has acquired all assets of Gauda, Inc., a developer of GPGPU-based computational lithography acceleration technology headquartered in Sunnyvale, Calif.

The acquisition, which includes all of Gauda's patents related to GPGPU acceleration as well as software, will strengthen D2S' capabilities in software for semiconductor manufacturing, including the increasingly critical area of wafer plane analysis—which evaluates how accurately complex shapes on advanced photomasks print as predicted on the wafer.

"The feedback that we've received from customers and partners has indicated that GPGPU acceleration will be increasingly critical to enable more accurate photomask writing and higher-yielding wafer lithography processes," stated Aki Fujimura, CEO of D2S. "The acquisition of Gauda provides important technology and intellectual property that will help extend the capabilities of our TrueMask product family and bolster our GPGPU offerings."

About D2S, Inc.
D2S is a supplier of a computational design platform to maximize eBeam technology to reduce mask costs for both low- and high-volume applications.  D2S TrueMask® solutions enable advanced photomask designs at 28-nm-and-below process nodes using complex shapes for superior wafer quality but within practical, cost-effective write-times using eBeam mask writing equipment.  D2S is the managing sponsor of the eBeam Initiative.  Headquartered in San Jose, Calif., the company was founded in 2007.  For more information, see: www.design2silicon.com.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.